Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 3/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.73 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.73 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8266174 | 1.00 | ADRB2 (1.00) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| Hydrochloric Acid SCHEMBL10872169 | 0.98 | ADRB2 (0.97) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL11232155 | 0.94 | ADRB2 (0.88) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL11667770 | 0.94 | ADRB2 (0.88) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| Acetamide SCHEMBL5800005 | 0.91 | ADRB2 (0.83) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL10743819 | 0.90 | CYP2D6 (0.81) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL10814311 | 0.88 | ADRB2 (0.78) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL10814305 | 0.88 | ADRB2 (0.78) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL10814431 | 0.88 | ADRB2 (0.78) | ADRB2ADRB1CYP2D6ADRB3PTGS1 | |
| SCHEMBL10746452 | 0.87 | CYP2D6 (0.77) | ADRB2ADRB1CYP2D6ADRB3PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105458161-B | A kind of powdered mold release agents composition | 浙江龙游展宇有机玻璃有限公司 | 2017-08-15 | — | — | CN | claimed |
| CN-110831584-B | Targeted drug rescue with novel compositions, combinations and methods thereof | 埃克塞瓦有限责任公司 | 2023-03-10 | — | — | CN | disclosed |
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | Exciva GmbH (DE) | 2022-10-25 | — | — | US | disclosed |
| US-11001701-B2 | PVC product and stabilizing agent thereof | NAN YA PLASTICS CORPORATION (TW) | 2021-05-11 | — | — | US | disclosed |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | VEPACHEDU SREENIVASARAO (US) | 2020-08-20 | — | — | US | disclosed |
| US-20200148858-A1 | PVC PRODUCT AND STABILIZING AGENT THEREOF | NAN YA PLASTICS CORPORATION (TW) | 2020-05-14 | — | — | US | disclosed |
| EP-3618819-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-11 | — | — | EP | disclosed |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | Exciva GmbH (DE) | 2020-03-05 | — | — | US | disclosed |
| WO-2018204713-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | EXCIVA UG (HAFTUNGSBESCHRÄNKT) (DE) | 2018-11-08 | — | — | WO | disclosed |
| US-7229782-B1 | Antibodies specific to multiple beta blockers and methods for their use | LABONE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229782-B1 | Antibodies specific to multiple beta blockers and methods for their use | LABONE, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-6239313-B1 | FROM AN INCLUSION COMPLEX OF EPOXIDE WITH CYCLODEXTRIN AND NUCLEOPHILIC COMPOUND | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2001-05-29 | — | — | US | disclosed |
| CN-1087630-A | Dihydrogen pyridine derivative and preparation method thereof | FUJISAWA PHARMACEUTICAL CO (JP) | 1994-06-08 | — | — | CN | disclosed |
| WO-1994002463-A1 | ANTIHYPERTENSIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-03 | — | — | WO | disclosed |
| EP-0193227-B1 | PROCESS FOR THE PREPARATION OF ARYLGLYCIDYL ETHERS AND 3-SUBSTITUTED 1-ALKYLAMINO-2-PROPANOLS | GIST-BROCADES N.V. (NL) | 1990-04-11 | — | — | EP | disclosed |
| EP-0193227-A1 | Process for the preparation of arylglycidyl ethers and 3-substituted 1-alkylamino-2-propanols | GIST-BROCADES N.V. (NL) | 1986-09-03 | — | — | EP | disclosed |
| EP-0013258-B1 | PROPENYL-SUBSTITUTED PHENOLGLYCIDYL ETHERS, PROCESS FOR THEIR PREPARATION AND THEIR USE | CIBA-GEIGY AG (CH) | 1982-07-07 | — | — | EP | disclosed |
| US-3742023-A | NOVEL 1-SUBSTITUTED PHENOXY-2-HYDROXY-3-ISOPROPYLAMINO-PROPANES | BOEHRINGER SOHN INGELHEIM | 1973-06-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11478467-B2 | Targeted drug rescue with novel compositions, combinations, and methods thereof | HTR2A, HTR2C, CYP3A43 | ADRB2 61/4885ADRB1 129/4885CYP2D6 9/4885 |
| US-20200069674-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2A, HTR2C, CYP3A43 | ADRB2 61/4885ADRB1 129/4885CYP2D6 9/4885 |
| US-20200261442-A1 | TARGETED DRUG RESCUE WITH NOVEL COMPOSITIONS, COMBINATIONS, AND METHODS THEREOF | HTR2C, HTR2A, HTR3A | ADRB2 89/4885ADRB1 208/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.